New prognostic model for patients with advanced gastric cancer: Fluoropyrimidine/platinum doublet for first-line chemotherapy

BACKGROUND: New prognostic factors have been reported in patients with metastatic or recurrent gastric cancer (MRGC), necessitating modifications to the previous prognostic model. AIM: To develop a new model, MRGC patients who received fluoropyrimidines/ platinum doublet chemotherapy between 2008 an...

Descripción completa

Detalles Bibliográficos
Autores principales: Koo, Dong-Hoe, Ryu, Min-Hee, Lee, Mi-Yeon, Moon, Mee-Sun, Kang, Yoon-Koo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2021
Materias:
Retrospective Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8717016/
https://www.ncbi.nlm.nih.gov/pubmed/35068874
http://dx.doi.org/10.3748/wjg.v27.i48.8357

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8717016/
https://www.ncbi.nlm.nih.gov/pubmed/35068874
http://dx.doi.org/10.3748/wjg.v27.i48.8357

Ejemplares similares